Pharmacology of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo-(F)-quinoxaline.
Ikonomidou
C
C
Department of Pediatric Neurology, Children's Hospital, Charité-Virchow Clinics, Berlin, Germany. ikonhr@ukrv.de
Turski
L
L
D000161:Acoustic Stimulation; D000818:Animals; D000927:Anticonvulsants; D001930:Brain Injuries / Q000188:drug therapy / Q000503:physiopathology*; D002545:Brain Ischemia / Q000188:drug therapy / Q000503:physiopathology*; D002540:Cerebral Cortex / Q000187:drug effects / Q000473:pathology; D003292:Convulsants; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D005106:Exploratory Behavior / Q000187:drug effects*; D007696:Kindling, Neurologic; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D018696:Neuroprotective Agents; D011810:Quinoxalines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012640:Seizures / Q000188:drug therapy / Q000503:physiopathology*; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000037:antagonists & inhibitors
D000927:Anticonvulsants; D003292:Convulsants; D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D011810:Quinoxalines; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid